Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Rankning i aktier #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Aktiekurs
$17.82
Senast synkroniserad: 2026-09-11
Marknadsvärde
$32.43B
Förändring (1 dag)
0.83%
Förändring (1 år)
-25.31%
Land
JP
Handel Daiichi Sankyo Company, Limited (4568)

Kategori

Vinst för Daiichi Sankyo Company, Limited (4568)
Vinst i Jun 2026 TTM: $1.65B
Enligt de senaste finansiella rapporterna från Daiichi Sankyo Company, Limited är företagets nuvarande vinst $1.65B. År 2024 hade företaget en vinst på $1.57B, en ökning jämfört med vinsten år 2023 som var $955.41M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Daiichi Sankyo Company, Limited från 2000 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
2026 (TTM) $1.65B -30.33%
2025 $2.37B 51.37%
2024 $1.57B 64.05%
2023 $955.41M 58.24%
2022 $603.78M -9.78%
2021 $669.24M -49.03%
2020 $1.31B 69.80%
2019 $773.25M 1.40%
2018 $762.56M -3.25%
2017 $788.16M -27.54%
2016 $1.09B 63.21%
2015 $666.47M -31.10%
2014 $967.36M -1.02%
2013 $977.31M 139.07%
2012 $408.79M -71.86%
2011 $1.45B 39.41%
2010 $1.04B -133.26%
2009 $-3.13B -287.21%
2008 $1.67B 55.54%
2007 $1.08B -7.55%
2006 $1.16B 60.36%
2005 $725.65M -8.51%
2004 $793.11M 29.61%
2003 $611.93M 0.45%
2002 $609.17M -8.18%
2001 $663.43M -26.55%
2000 $903.21M 0.00%
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
$33.59B 1,932.41%
US
$25.20B 1,424.32%
US
$8.70B 426.28%
US
$21.39B 1,193.96%
CH
$5.95B 259.84%
US